A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors (NCT05536141)
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose expansion stage.
Who can join: Review the eligibility criteria below.
Location: Research Site — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (25 Sites)
- Research Site — Birmingham, Alabama
- Research Site — San Diego, California
- Research Site — Santa Monica, California
- Research Site — Miami, Florida
- Research Site — Atlanta, Georgia
- Research Site — Louisville, Kentucky
- Research Site — New Orleans, Louisiana
- Research Site — Baltimore, Maryland
- Research Site — Boston, Massachusetts
- Research Site — Detroit, Michigan
- Research Site — Detroit, Michigan
- Research Site — Omaha, Nebraska
- Research Site — New York, New York
- Research Site — New York, New York
- Research Site — Cleveland, Ohio
- Research Site — Cleveland, Ohio
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Nashville, Tennessee
- Research Site — Nashville, Tennessee
- Research Site — San Antonio, Texas
- Research Site — Camperdown,
- Research Site — Melbourne,
- Research Site — Sydney,
- Research Site — Seoul,
- Research Site — Barcelona,
📞 Contact the Study Coordinator
Phone: (510) 462-3330
Email: ClinicalTrialInquiry@arcusbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Clear Cell Renal Cell Carcinoma
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery — Fairbanks, Alaska
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer — Los Angeles, California
- Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors — Duarte, California
- A Phase 1/2 Trial of ADI-270 in ccRCC — Redwood City, California
- Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab — Iowa City, Iowa
- Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer — Westwood, Kansas
Explore by condition: All Clear Cell Renal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.